<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Product Guide &#187; Obesity</title>
	<atom:link href="http://www.pharmaceuticalproductguide.com/blog/category/obesity/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaceuticalproductguide.com/blog</link>
	<description>A comprehensive guide to pharmaceutical products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:15:33 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Positive appraisal for Acomplia from NICE</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2008/04/07/positive-appraisal-for-acomplia-from-nice/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2008/04/07/positive-appraisal-for-acomplia-from-nice/#comments</comments>
		<pubDate>Mon, 07 Apr 2008 23:55:29 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[Obesity]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Acomplia]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[obesity drug]]></category>
		<category><![CDATA[overweight patients]]></category>
		<category><![CDATA[Positive appraisal]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/2008/04/07/positive-appraisal-for-acomplia-from-nice/</guid>
		<description><![CDATA[Acomplia, the obesity drug manufactured by Sanofi-Aventis, has received a positive final appraisal determination from the National Institute for Health and Clinical Excellence (NICE) in the U.K. The body has also guided to the use of Acomplia as a support for diet and exercise in overweight patients who have not responded to other obesity agents.
]]></description>
			<content:encoded><![CDATA[<p><img border="1" vspace="5" align="left" width="218" src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2008/04/sanofi-aventis-logo.jpg" hspace="5" alt="Sanofi aventis logo" height="86" />Acomplia, the obesity drug manufactured by <a href="http://www.sanofi-aventis.us/index.html">Sanofi-Aventis</a>, has received a positive final appraisal determination from the National Institute for Health and Clinical Excellence (NICE) in the U.K. The body has also guided to the use of Acomplia as a support for diet and exercise in overweight patients who have not responded to other obesity agents.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2008/04/07/positive-appraisal-for-acomplia-from-nice/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
